Standout Papers

Cancer statistics in China, 2015 2016 2026 2019 2022 13.8k
  1. Cancer statistics in China, 2015 (2016)
    Wanqing Chen, Rongshou Zheng et al. CA A Cancer Journal for Clinicians
  2. Cancer incidence and mortality in China, 2016 (2022)
    Rongshou Zheng, Siwei Zhang et al. SHILAP Revista de lepidopterología
  3. Cancer incidence and mortality in China, 2022 (2024)
    Bingfeng Han, Rongshou Zheng et al. SHILAP Revista de lepidopterología
  4. [Report of cancer epidemiology in China, 2015]. (2019)
    Rongshou Zheng, Kexin Sun et al. PubMed
  5. Cuproptosis: mechanisms and links with cancers (2023)
    Jiaming Xie, Yannan Yang et al. Molecular Cancer
  6. Cancer incidence and mortality in China, 2013 (2017)
    Wanqing Chen, Rongshou Zheng et al. Cancer Letters
  7. Annual report on status of cancer in China, 2011. (2015)
    Wanqing Chen, Rongshou Zheng et al. PubMed
  8. Cancer registration in China and its role in cancer prevention and control (2020)
    Wenqiang Wei, Hongmei Zeng et al. The Lancet Oncology
  9. Epidemiology of Lung Cancer (2016)
    Yousheng Mao, Ding Yang et al. Surgical Oncology Clinics of North America
  10. Cancer incidence and mortality in China, 2015 (2020)
    Siwei Zhang, Kexin Sun et al. SHILAP Revista de lepidopterología
  11. [Cancer incidence and mortality in China, 2022]. (2024)
    Rongshou Zheng, Bingfeng Han et al. PubMed
  12. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis (2021)
    Xiaoxiang Zhou, Zhuoran Yao et al. The Lancet Oncology
  13. Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea (2022)
    Rongshou Zheng, Siwei Zhang et al. Science China Life Sciences
  14. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN (2024)
    Shaoming Wang, Rongshou Zheng et al. ˜The œLancet. Gastroenterology & hepatology
  15. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC (2023)
    Tina Cascone, Mark M. Awad et al. Annals of Oncology
  16. Cancer survival statistics in China 2019–2021: a multicenter, population-based study (2024)
    Hongmei Zeng, Rongshou Zheng et al. SHILAP Revista de lepidopterología

Immediate Impact

5 by Nobel laureates 11 from Science/Nature 53 standout
Sub-graph 1 of 21

Citing Papers

Pancreatic cancer
2025 Standout
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
1 intermediate paper

Works of Jie He being referenced

Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN
2024 Standout
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
2021
and 1 more

Author Peers

Author Last Decade Papers Cites
Jie He 10938 8851 13842 9707 616 33.2k
Wanqing Chen 10560 7686 11062 7946 291 30.2k
Yu Shyr 9760 6380 11557 6004 541 32.4k
Ming‐Sound Tsao 14968 13475 16214 8193 644 36.3k
Holger Moch 11099 14366 17943 9529 602 35.4k
Rui‐Hua Xu 9398 6140 12536 9280 812 26.6k
Scott M. Lippman 12512 10375 13300 7757 520 36.3k
Siwei Zhang 9752 6856 10771 7619 231 27.6k
Richard Pazdur 19104 9902 10270 4972 582 36.2k
Rongshou Zheng 10019 7214 10423 7630 203 27.9k
Waun Ki Hong 12563 7980 16651 5447 505 33.5k

All Works

Loading papers...

Rankless by CCL
2026